{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:39:02Z","timestamp":1791005942189,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:00:00Z","timestamp":1601078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010810","name":"\u00d6gonfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003945","name":"Link\u00f6pings Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.heliyon.2020.e05105","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T16:07:36Z","timestamp":1601654856000},"page":"e05105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Collagen-based scaffolds with infused anti-VEGF release system as potential cornea substitute for high-risk keratoplasty: A preliminary in vitro evaluation"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-6258","authenticated-orcid":false,"given":"Oleksiy","family":"Buznyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Azharuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Fagerholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Pasyechnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6142-5489","authenticated-orcid":false,"given":"Hirak K.","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2020.e05105_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4103\/0301-4738.100540","article-title":"Turning the tide of corneal blindness","volume":"60","author":"Oliva","year":"2012","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.heliyon.2020.e05105_bib2","first-page":"227","article-title":"Childhood blindness in context of VISION 2020: the right to sight: a global initiative to eliminate avoidable blindness","volume":"79","author":"Gilbert","year":"2001","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.heliyon.2020.e05105_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00003226-200201000-00001","article-title":"Summary of corneal transplant activity: eye bank association of America","volume":"21","author":"Aiken-O'Neill","year":"2002","journal-title":"Cornea"},{"key":"10.1016\/j.heliyon.2020.e05105_bib4","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1016\/S0142-9612(01)00168-5","article-title":"An overview of the development of artificial corneas with porous skirts and the use of PHEMA for such an application","volume":"22","author":"Chirila","year":"2001","journal-title":"Biomaterials"},{"issue":"46","key":"10.1016\/j.heliyon.2020.e05105_bib5","doi-asserted-by":"crossref","first-page":"46ra61","DOI":"10.1126\/scitranslmed.3001022","article-title":"A\u00a0biosynthetic alternative to human donor tissue for inducing corneal regeneration: 24-month follow-up of a phase 1 clinical study","volume":"2","author":"Fagerholm","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2020.e05105_bib6","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1016\/j.biomaterials.2013.11.079","article-title":"Stable corneal regeneration four years after implantation of a cell-free recombinant human collagen scaffold","volume":"35","author":"Fagerholm","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.heliyon.2020.e05105_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cts.12293","article-title":"Bioengineered corneas grafted as alternatives to human donor corneas in three high-risk patients","volume":"8","author":"Buznyk","year":"2015","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.heliyon.2020.e05105_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/1875043501003010010","article-title":"Controlled release of acyclovir through bioengineered corneal implants with silica nanoparticle carriers","volume":"3","author":"Bareiss","year":"2010","journal-title":"Open Tissue Eng. Regen. Med. J."},{"key":"10.1016\/j.heliyon.2020.e05105_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.3.3.4","article-title":"Cathelicidin LL-37 and HSV-1 corneal infection: peptide versus gene therapy","volume":"3","author":"Lee","year":"2014","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.heliyon.2020.e05105_bib10","doi-asserted-by":"crossref","first-page":"1903760","DOI":"10.1002\/adfm.201903760","article-title":"Rational nanotoolbox with theranostic potential for medicated pro-regenerative corneal implants","volume":"29","author":"Patra","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.heliyon.2020.e05105_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/bja\/aer398","article-title":"Tissue and corneal donation and transplantation in the UK","volume":"108","author":"Gaum","year":"2012","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.heliyon.2020.e05105_bib12","first-page":"197","article-title":"Eye banking in India: a road ahead","volume":"23","author":"Sangwan","year":"2010","journal-title":"J.\u00a0Int. Med. Sci. Acad."},{"key":"10.1016\/j.heliyon.2020.e05105_bib13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/ICO.0b013e3182014668","article-title":"The New Zeland National Eye Bank: survival and visual outcome 1 year after penetrating keratoplasty","author":"Patel","year":"2011","journal-title":"Cornea"},{"issue":"Suppl 9","key":"10.1016\/j.heliyon.2020.e05105_bib14","first-page":"6","article-title":"Corneal allograft rejection: immunopathogenesis to therapeutics","author":"Qazi","year":"2013","journal-title":"J.\u00a0Clin. Cell. Immunol."},{"key":"10.1016\/j.heliyon.2020.e05105_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10792-014-9938-4","article-title":"Subconjunctival and\/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival","volume":"35","author":"Fasciani","year":"2015","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.heliyon.2020.e05105_bib16","first-page":"1001","article-title":"Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development","volume":"9","author":"Agarwal","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.heliyon.2020.e05105_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","article-title":"Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)","volume":"10","author":"Stevenson","year":"2012","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.heliyon.2020.e05105_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nano.2007.03.005","article-title":"Cell selective response to gold nanoparticles","volume":"3","author":"Patra","year":"2007","journal-title":"Nanomedicine"},{"key":"10.1016\/j.heliyon.2020.e05105_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40199-014-0085-2","article-title":"Effect of peptide length on the conjugation to the gold nanoparticle surface: a molecular dynamic study","volume":"23","author":"Ramezani","year":"2015","journal-title":"Daru J. Pharm. Sci."},{"key":"10.1016\/j.heliyon.2020.e05105_bib20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1039\/C7BM00006E","article-title":"Peptide-functionalized gold nanoparticles: versatile biomaterials for diagnostic and therapeutic applications","volume":"5","author":"Zong","year":"2017","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.heliyon.2020.e05105_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/HAB-2011-0244","article-title":"Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin\u2122) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies","volume":"20","author":"Kaja","year":"2011","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.heliyon.2020.e05105_bib22","doi-asserted-by":"crossref","first-page":"9425","DOI":"10.1021\/ac901822w","article-title":"Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation and biomolecular binding studies","volume":"81","author":"Jans","year":"2009","journal-title":"Anal. Chem."},{"key":"10.1016\/j.heliyon.2020.e05105_bib23","doi-asserted-by":"crossref","first-page":"10958","DOI":"10.1021\/ja048749n","article-title":"Label-free colorimetric detection of specific sequences in genomic DNA amplified by the polymerase chain reaction","volume":"126","author":"Li","year":"2004","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.heliyon.2020.e05105_bib24","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1021\/acs.bioconjchem.7b00489","article-title":"Less is more: a comparison of antibody-gold nanoparticle conjugates of different ratios","volume":"28","author":"Byzova","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.heliyon.2020.e05105_bib25","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00417-009-1170-y","article-title":"Avastin use in high risk corneal transplantation","volume":"247","author":"Vassileva","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.heliyon.2020.e05105_bib26","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s40265-014-0302-9","article-title":"Bevacizumab: a review of its use in advanced cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2020.e05105_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/ICU.0b013e32835fefee","article-title":"Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration","volume":"24","author":"Scott","year":"2013","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.heliyon.2020.e05105_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.sjopt.2017.02.008","article-title":"Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization","volume":"31","author":"Al-Debasi","year":"2017","journal-title":"Saudi J. Ophthalmol."},{"key":"10.1016\/j.heliyon.2020.e05105_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-03959-4","article-title":"A\u00a0new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles","volume":"7","author":"Sousa","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2020.e05105_bib30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijbiomac.2013.05.034","article-title":"Sustained release of Avastin\u00ae from polysaccharides cross-linked hydrogels for ocular drug delivery","volume":"60","author":"Xu","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.heliyon.2020.e05105_bib31","first-page":"1397","article-title":"Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation, Artif. Cells","volume":"45","author":"Pandit","year":"2017","journal-title":"Nanomed. Biotechnol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020319484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020319484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:14:57Z","timestamp":1773861297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844020319484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2405844020319484"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e05105","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/862607","asserted-by":"object"}]},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Collagen-based scaffolds with infused anti-VEGF release system as potential cornea substitute for high-risk keratoplasty: A preliminary in vitro evaluation","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e05105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e05105"}}